Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.48 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.48 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20214001 | 0.86 | CHRNB2 (0.35) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL24045623 | 0.80 | — | — | |
| SCHEMBL19014334 | 0.80 | — | — | |
| SCHEMBL20636195 | 0.78 | — | — | |
| SCHEMBL1333807 | 0.78 | NR1H2 (0.50) | SMN1; SMN2KDM4EEPHX2EPHX1 | |
| SCHEMBL28789525 | 0.75 | CHRNB2 (0.30) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL24045673 | 0.75 | CHRNB2 (0.30) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL18340862 | 0.75 | ATM (0.42) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL2873876 | 0.74 | ESR1 (0.32) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL2003186 | 0.74 | ESR1 (0.32) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933116-B2 | Gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933116-B2 | Gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-01-16 | — | — | US | disclosed |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-01-16 | — | — | US | disclosed |
| EP-0717042-B1 | Process for preparing 1-(4,5-Dihydro-2-thiazolyle)-3-azetidine thiol derivatives | WYETH LEDERLE JAPAN LTD (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5783703-A | CARBAPENEM INTERMEDIATES | LEDERLE (JAPAN), LTD. (JP) | 1998-07-21 | — | — | US | disclosed |
| US-5659043-A | BACTERICIDES | LEDERLE (JAPAN) LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0717042-A1 | 1-(4,5-Dihydro-2-thiazolyle)-3-azetidine thiol derivatives | LEDERLE (JAPAN), Ltd. (JP) | 1996-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | CHRNB2 277/4885CHRNA3 364/4885CHRNA4 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.